Theravance Biopharma Stock News

Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.

The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a

pupunkkop This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Fo

Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2024 Earnings Call Transcript May 13, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhonda

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.

Q1 2024 YUPELRI® (revefenacin) net sales of $55.2 million, recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboration revenue of $14.5 million, increased 39% versus Q1 2023, reflecting

DUBLIN , May 9, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Monday, Ma

DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 1

The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro

Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre

DUBLIN , April 10, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM E

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

The life of a bearish speculator can be dangerous and that's part of the appeal of short-squeeze stocks: you can make life miserable for those attempting to cynically extract profits from others' mise

Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time.